• Users Online: 808
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 1  |  Issue : 1  |  Page : 7-11


Department of Dermatology, Seth GS Medical College, KEM Hospital, Parel, Mumbai, Maharashtra, India

Correspondence Address:
Kinjal Deepak Rambhia
B-105 Kalpataru Classic, Chincholi Bunder Road, Malad West, Mumbai - 400 064, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/WKMP-0110.170765

Rights and Permissions

Adalimumab is a biological agent which acts by inhibiting tumor necrosis factor-alpha. It has been used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and moderate to severe chronic plaque psoriasis. Various studies show good efficacy in psoriasis cases, unresponsive or partially responsive to other systemic therapies and even cases of resistance to other biologics. It has helped reduce the morbidity significantly and improved the quality of life of psoriatics. Although majority of the experience of this drug is from its use in rheumatoid arthritis, this biologic has generally been considered safe even for psoriasis and other dermatologic conditions.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded297    
    Comments [Add]    

Recommend this journal